83 results on '"Pritchard, Kathleen I"'
Search Results
2. Effect of Metformin vs Placebo on Weight and Metabolic Factors in NCIC CTG MA.32
3. Validated or Not Validated? That Is the Question
4. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
5. Regional Nodal Irradiation in Early-Stage Breast Cancer
6. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
7. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial
8. Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2
9. Response
10. CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned
11. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
12. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients
13. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial
14. Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial
15. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer
16. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents
17. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
18. High levels of uPA and PAI-1 predict a good response to anthracyclines
19. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
20. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients
21. Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2
22. Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
23. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome
24. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?
25. Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer
26. Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial
27. Lymphedema in women with breast cancer: Characteristics of patients screened for a randomized trial
28. Antihormone Therapy in Recurrent Metastatic Breast Cancer
29. HER2/neu in systemic therapy for women with breast cancer: a systematic review
30. HER2/neu in systemic therapy for women with breast cancer: A systematic review
31. Should Observational Studies Be a Thing of the Past?
32. Combining Endocrine Agents With Chemotherapy: Which Patients and What Sequence?
33. Endocrine and Targeted Manipulation of Breast Cancer: Summary Statement for The Sixth Cambridge Conference
34. Do Adjuvant Aromatase Inhibitors Increase the Cardiovascular Risk in Postmenopausal Women With Early Breast Cancer: Meta-Analysis of Randomized Trials
35. Tamoxifen-Associated Hot Flashes in Women
36. Adjuvant Therapy for Breast Cancer: We Are Solving the Puzzle, But Pieces Are Still Missing
37. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19
38. Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy
39. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
40. Anthracyclines in Early Breast Cancer
41. Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17
42. Biological Significance of Occult Micrometastases in Histologically Negative Axillary Lymph Nodes in Breast Cancer Patients Using the Recent American Joint Committee on Cancer Breast Cancer Staging System
43. HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
44. Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care
45. Cardiovascular Health and Aromatase Inhibitors
46. Ascertaining Prognosis for Breast Cancer in Node-Negative Patients with Innovative Survival Analysis
47. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study
48. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
49. Incidence and Prognostic Impact of Amenorrhea During Adjuvant Therapy in High-Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5
50. Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.